These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17719783)

  • 1. Application of aromatase inhibitors in endocrine responsive breast cancers.
    Goss P; Wu M
    Breast; 2007 Dec; 16 Suppl 2():S114-9. PubMed ID: 17719783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant endocrine treatment of early breast cancer.
    Lønning PE
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
    Cleator SJ; Ahamed E; Coombes RC; Palmieri C
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
    Smith IE; Arnedos M
    Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
    Burdette-Radoux S; Muss HB
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
    Iwase H
    Breast Cancer; 2008; 15(4):278-90. PubMed ID: 18810576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
    Snoj N; Paridaens R; Cufer T
    Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aromatase inhibitors in advanced breast cancer].
    Spinelli GP; Tomao F; Miele E; Pasciuti G; Russillo M; Tomao S
    Recenti Prog Med; 2008 Jan; 99(1):34-8. PubMed ID: 18389871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L; Clavarezza M; Venturini M
    Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.